Roche's BTK inhibitor put on partial hold over concerns about potential liver injury
Roche’s fenebrutinib program in multiple sclerosis has been put on partial clinical hold over potential cases of drug-induced liver injury, the company said Thursday.
The BTK inhibitor class has been troubled by liver injury cases, with Merck KGaA’s evobrutinib in relapsing multiple sclerosis (RMS) and Sanofi’s tolebrutinib in multiple sclerosis and myasthenia gravis receiving partial holds in June 2022 and April 2023, respectively. While several BTK inhibitors are currently on the market to treat blood cancers, researchers believe blocking the enzyme can also help treat chronic inflammatory and autoimmune diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.